UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction
of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 3, 2022, Second Sight Medical Products, Inc. (“Second Sight”) received notice from Edward Randolph, its Chief Operating Officer, that he will resign from his current position effective August 19, 2022. Mr. Randolph has served Second Sight since 2007. Mr. Randolph’s resignation did not result from a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |||
| 104 | The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. | |||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SECOND SIGHT MEDICAL PRODUCTS, INC. | ||
| Date: August 5, 2022 | By: | /s/ Scott Dunbar |
| Scott Dunbar | ||
| Acting Chief Executive Officer | ||
Cover |
Aug. 03, 2022 |
|---|---|
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Aug. 03, 2022 |
| Entity File Number | 001-36747 |
| Entity Registrant Name | SECOND SIGHT MEDICAL PRODUCTS, INC. |
| Entity Central Index Key | 0001266806 |
| Entity Tax Identification Number | 02-0692322 |
| Entity Incorporation, State or Country Code | CA |
| Entity Address, Address Line One | 13170 Telfair Ave |
| Entity Address, City or Town | Sylmar |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 91342 |
| City Area Code | (818) |
| Local Phone Number | 833-5000 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Emerging Growth Company | false |
| Entity Information, Former Legal or Registered Name | Not Applicable |
| Common Stock [Member] | |
| Title of 12(b) Security | Common Stock |
| Trading Symbol | EYES |
| Security Exchange Name | NASDAQ |
| Warrants [Member] | |
| Title of 12(b) Security | Warrants |
| Trading Symbol | EYESW |
| Security Exchange Name | NASDAQ |